PHIO

Phio Pharmaceuticals Corp

0.9788

Oct 09 • 3:59 PM ET +0.0057 (0.59%)

0.9835

Aftermarket • 6:41 PM ET +0.0047 (0.48%)

Healthcare Biotechnology USA Nano NASD

Peers: BLRX GDTC GTBP ICU INTS KRSA TOVX BIVI ERNA GNTA

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	11.37M
Enterprise Value	-1.63M
Income	-12.90M
Sales	0.00M
Book/sh	1.08
Cash/sh	1.12
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	May 10, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.90
P/C	0.87
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.39
Current Ratio	8.39
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.34
EPS next Y	-0.61
EPS next Q	-0.36
EPS this Y	0.34%
EPS next Y	57.79%
EPS next 5Y	-
EPS past 3/5Y	74.81% 62.91%
Sales past 3/5Y	- -
EPS Y/Y TTM	59.81%
Sales Y/Y TTM	-
EPS Q/Q	21.14%
Sales Q/Q	-
Earnings	Aug 07 BMO
EPS/Sales Surpr.	0.00% -

Insider Own	15.07%
Insider Trans	3.89%
Inst Own	5.57%
Inst Trans	-0.23%
ROA	-100.78%
ROE	-113.71%
ROIC	-102.40%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.85%
SMA50	-7.51%
SMA200	-11.40%
Trades

Shs Outstand	11.62M
Shs Float	9.87M
Short Float	0.91%
Short Ratio	0.16
Short Interest	0.09M
52W High	4.19 -76.64%
52W Low	0.81 20.44%
Volatility	5.98% 4.95%
ATR (14)	0.05
RSI (14)	39.25
Beta	0.92
Rel Volume	0.08
Avg Volume	576.48K
Volume	43,353

Perf Week	-0.64%
Perf Month	-3.09%
Perf Quarter	-2.12%
Perf Half Y	-19.11%
Perf YTD	-6.78%
Perf Year	-58.53%
Perf 3Y	-92.09%
Perf 5Y	-99.50%
Perf 10Y	-100.00%
Recom	1.00
Target Price	14.00
Prev Close	0.97
Price	0.98
Change %	0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-25	Resumed	H.C. Wainwright	Buy	$14
Aug-05-20	Initiated	H.C. Wainwright	Buy	$4

Oct-06-26 07:00AM	Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026 (Newsfile)
Oct-05-26 07:00AM	Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference (Newsfile)
Sep-23-26 07:00AM	Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference (Newsfile Corp.)
Sep-14-26 07:00AM	Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma (Newsfile)
Sep-11-26 09:00AM	Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (Newsfile Corp.)
07:00AM	Loading…
Aug-11-26 07:00AM	Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 (Newsfile)
Aug-06-26 04:05PM	Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update (Newsfile Corp.)
Jul-22-26 12:30PM	Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile) -6.19%
07:00AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile Corp.)
Jul-21-26 07:00AM	Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors (Newsfile Corp.)
Jul-15-26 11:06AM	Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones (InvestorsHub) -13.58%
07:00AM	Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision (Newsfile)
Jun-26-26 07:00AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
Jun-25-26 07:00AM	Phio Pharmaceuticals Announces 'How siRNA Therapy can Change the Course of Cancer Treatment' in a Fireside Chat with Force Family Office on Monday, June 29, 2026 (Newsfile) -5.90%
Jun-24-26 07:00AM	Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 (Newsfile Corp.)
07:00AM	Loading…
Jun-18-26 07:00AM	Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026 (Newsfile)
May-26-26 07:00AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
May-12-26 07:00AM	Phio Pharmaceuticals Announces 'Innovations in Skin Cancer Treatment and Prevention' in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026 (Newsfile)
May-07-26 04:05PM	Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update (Newsfile) -6.14%
Apr-23-26 07:00AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
Apr-13-26 07:00AM	Phio Pharmaceuticals Announces 'Nobel Prize Winning Science Takes on Skin Cancer' in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026 (Newsfile)
Apr-09-26 07:00AM	Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 (Newsfile)
Mar-30-26 07:00AM	Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 (Newsfile Corp.)
Mar-23-26 07:00AM	Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement (Newsfile)
Mar-16-26 11:30AM	Phio Pharmaceuticals Announces 'A Groundbreaking Approach to Treating Skin Cancer' in a Fireside Chat with Force Family Office (Newsfile) +7.69%
Mar-10-26 07:00AM	Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT (Newsfile)
Mar-05-26 04:05PM	Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update (Newsfile)
07:00AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
Feb-23-26 09:45AM	Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company (NewMediaWire)
Feb-19-26 07:00AM	Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 (Newsfile)
08:43AM	Loading…
Feb-12-26 08:43AM	What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? (Benzinga) -5.43%
Feb-10-26 11:12AM	Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients (Benzinga) +24.44%
07:00AM	Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial (Newsfile)
Jan-26-26 08:15AM	Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference (Newsfile)
Jan-20-26 09:30AM	Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial (Newsfile) -5.26%
Jan-15-26 08:45AM	Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026 (Newsfile)
Dec-23-25 08:45AM	Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 (Newsfile) -6.36%
Nov-25-25 11:30AM	Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 (Newsfile)
Nov-17-25 08:45AM	Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress (Newsfile)
Nov-13-25 04:15PM	Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (Newsfile) -9.49% -9.09%
Nov-07-25 10:30AM	Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 (Newsfile) +5.41%
07:45AM	Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program (Newsfile)
Nov-03-25 01:40PM	Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds (Newsfile) -9.27%
07:45AM	Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial (Newsfile)
Oct-31-25 10:15AM	Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director (Newsfile)
Oct-21-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
Sep-23-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
Sep-18-25 07:45AM	Phio Pharmaceuticals to Present at the Life Sciences Future Conference (Newsfile)
Sep-03-25 07:45AM	Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Newsfile)
Aug-14-25 04:15PM	Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (Newsfile)
Jul-25-25 03:04PM	Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds (Newsfile) +9.16%
12:36PM	Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort (Newsfile)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:45AM	Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance (Newsfile)
Jun-25-25 07:45AM	Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort (Newsfile)
Jun-24-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Jun-06-25 07:45AM	Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio (Newsfile) +20.33%
May-28-25 09:02AM	Best Value Stocks to Buy for May 28th (Zacks) +16.96%
04:37AM	New Strong Buy Stocks for May 28th (Zacks)
May-20-25 08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-19-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference (Newsfile)
May-15-25 04:15PM	Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (Newsfile)
May-07-25 07:45AM	Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial (Newsfile) +18.60%
May-01-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Apr-23-25 10:15AM	Best Momentum Stocks to Buy for April 23rd (Zacks) -18.73%
06:45AM	Best Value Stocks to Buy for April 23rd (Zacks)
Apr-10-25 10:53AM	PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose (Zacks) +7.14%
Apr-09-25 07:45AM	Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort (Newsfile) +52.48%
Apr-03-25 07:45AM	Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894 (Newsfile)
Mar-31-25 04:00PM	Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update (Newsfile) -5.38%
Mar-10-25 07:45AM	American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting (Newsfile)
Mar-05-25 07:45AM	Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study (Newsfile) +5.30%
Feb-26-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Feb-20-25 07:45AM	Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors (Newsfile)
Feb-03-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Jan-22-25 07:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) -7.66%
Jan-21-25 11:15AM	Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -10.47%
Jan-16-25 01:00PM	Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) +9.40%
Jan-15-25 07:00AM	Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -25.70%
Jan-14-25 07:00AM	Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -45.76%
Jan-13-25 12:45PM	Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why (Benzinga) +290.53%
07:45AM	Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762 (Newsfile)
Jan-02-25 07:45AM	Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology (Newsfile) +5.56%
Dec-23-24 01:15PM	Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) +26.70%
Dec-19-24 02:28PM	Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -30.68%
07:45AM	Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762 (Newsfile)
Dec-12-24 09:21AM	Phio Pharmaceuticals Announces Publication in Frontiers in Immunology (Newsfile) +6.34%
Dec-10-24 07:45AM	Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award (Newsfile)
Dec-03-24 07:45AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Nov-19-24 07:45AM	Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study (Newsfile) +12.42%
Nov-14-24 05:47PM	Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (Newsfile) -5.11%
Nov-07-24 10:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Newsfile)
Nov-01-24 07:45AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Oct-24-24 08:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Newsfile)
Oct-18-24 01:30PM	Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) +9.81%
08:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series (Newsfile)
Oct-16-24 08:00AM	Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference (Newsfile) +17.75%
Oct-07-24 08:00AM	Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells (Newsfile) -6.17%
Oct-02-24 04:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) -6.47%
Oct-01-24 08:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference (Newsfile)

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the proprietary INTASYL small interfering RNA gene silencing technology designed to make immune cells more effective in killing tumor cells. Its pipelines include PH-762 and PH-894. The company was founded on September 8, 2011 and is headquartered in King of Prussia, PA.

PresidentMr. Robert J. Bitterman

CFOMs. Lisa C. Carson

Senior Vice President of DevelopmentMs. Linda M. Mahoney

Senior Vice President of Regulatory & Corporate AffairsDr. Jennifer Phillips Pharm.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Plott Ronald Todd	Director	Sep 29 '26	Buy	1.04	5,000	5,200	42,000	Sep 30 04:01 PM
Plott Ronald Todd	Director	Sep 28 '26	Buy	1.03	5,000	5,150	37,000	Sep 30 04:01 PM
BRADFORD PATRICIA A	Director	Sep 24 '26	Buy	1.01	6,500	6,583	64,151	Sep 25 04:01 PM
Bitterman Robert J	Chairman, Pres. & CEO	Sep 22 '26	Buy	1.03	2,000	2,058	364,871	Sep 23 04:01 PM
BRADFORD PATRICIA A	Director	Sep 15 '26	Buy	1.03	12,000	12,360	57,651	Sep 16 04:01 PM
Plott Ronald Todd	Director	Aug 19 '26	Buy	1.14	15,000	17,100	15,000	Aug 20 08:30 AM
Bitterman Robert J	Chairman, Pres. & CEO	Aug 18 '26	Buy	1.06	10,000	10,600	431,421	Aug 19 04:01 PM
Bitterman Robert J	Chairman, Pres. & CEO	Jun 26 '26	Buy	0.99	10,000	9,900	421,421	Jun 29 04:02 PM
Bitterman Robert J	Chairman, Pres. & CEO	Dec 31 '25	Buy	1.03	5,000	5,150	291,421	Jan 02 04:05 PM
Bitterman Robert J	Chairman, Pres. & CEO	Dec 23 '25	Buy	1.02	5,000	5,100	286,421	Dec 29 08:10 AM
Bitterman Robert J	Chairman, Pres. & CEO	Nov 21 '25	Buy	1.14	5,000	5,700	281,421	Nov 24 12:54 PM
Bitterman Robert J	Chairman, Pres. & CEO	Nov 18 '25	Buy	1.27	5,000	6,350	276,421	Nov 19 12:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHIO

Phio Pharmaceuticals Corp

Upgrade your Finviz experience